RP2-Related Retinopathy: Comprehensive Disease Characteristics Report

1. Disease Information

Overview: RP2-related retinopathy (also termed RP2-associated X-linked retinitis pigmentosa) is a form of inherited retinal degeneration caused by hemizygous pathogenic variants in the RP2 gene on the X chromosome. It presents in males as a severe, early-onset, rapidly progressive rod-cone dystrophy, and in female carriers as a highly variable phenotype ranging from asymptomatic to RP-level vision loss due to X-inactivation (Lyonization). RP2 was the second gene identified as a cause of X-linked retinitis pigmentosa (XLRP), historically accounting for roughly 10–20% of XLRP cases (some sources cite up to 16–20%), with RPGR accounting for the majority (~60–75%) (PMC3124502, PMC5353642).

Key identifiers: - Gene/OMIM disease entry: RP2, OMIM #312600 (Retinitis Pigmentosa 2); gene locus OMIM 300757 (RP2 Activator of ARL3 GTPase) - Related OMIM entries: #268000 (Retinitis Pigmentosa, general); #300455 (X-linked RP and sinorespiratory infections ± deafness, RPSRDF — contiguous gene deletion syndrome involving RP2) - Gene location: Xp11.3 (5 exons, ~1,050 bp coding sequence, 350 amino acid protein) - Orphanet: ORPHA791 (Retinitis pigmentosa, umbrella term); a gene-specific Orphanet entry also exists for RP2-related XLRP - MONDO: MONDO:0100442 (RP2-related retinopathy, per task); umbrella RP term MONDO:0019200 - ICD-10: H35.52 (pigmentary retinal dystrophy), broader H35.5 - MeSH: Retinitis Pigmentosa (D012174) - Disease Ontology:* DOID:10584

Data source type: This report synthesizes aggregated disease-level literature — natural history cohort studies, case series, functional/molecular studies, and model organism data — rather than individual EHR-derived data.

2. Etiology

Disease causal factor: Purely genetic/monogenic. Hemizygous (males) or heterozygous (females, with variable expressivity) loss-of-function or dysfunction-causing variants in RP2 cause disease; no environmental or infectious cause is established.

Genetic risk factors: - Causal variants in RP2: nonsense, frameshift, splice-site, and missense variants, plus whole-gene/partial-gene deletions (PMC10190057; PMC9738434 natural history study found 5 nonsense, 6 frameshift, 1 splice-site, 1 missense among 24 variants in one cohort). - X-linked inheritance means male sex is itself a major risk determinant for full-penetrance disease. - Family history of X-linked disease — but per PMC11139645 (female carrier study), "family history of affected females with RP does not exclude X-linked disease," since carrier females can be symptomatic.

Environmental/lifestyle risk factors: None specifically established for RP2; as with RP broadly, no consistent environmental modifiers are documented in the reviewed literature.

Protective factors: No validated genetic or environmental protective factors specific to RP2 were identified in the literature searched. In female carriers, favorable (non-random) X-inactivation skewing toward the mutant allele functions as a protective factor at the individual level (PMC11139645): "The disease spectrum is likely explained by Lyonization, whereby random X-chromosome inactivation during embryogenesis leads to variable expression of the wild-type phenotype."

Gene-environment interactions: None specifically documented for RP2; vitamin A/E supplementation interactions are described for RP broadly (see Prevention/Treatment) but not RP2-specific.

Modifier genes: No validated modifier genes were reported; the natural history study (PMC9738434) explicitly found "no evidence of genotype–phenotype correlation" among variant types, and female carrier phenotype is modified primarily by X-inactivation pattern rather than a second gene.

3. Phenotypes

Male (hemizygous) patients — from natural history study of 47 males/33 families (PMC9738434, Ophthalmology 2022/2023, PMC10567581):

Table (click to expand)

Phenotype	Frequency	HPO term (suggested)
Nyctalopia (night blindness) — first symptom	69.6%	HP:0000662
Reduced visual acuity as first symptom	13.0%	HP:0000572 (Visual impairment)
Nyctalopia + reduced vision combined onset	8.7%	—
Nystagmus	4.4%	HP:0000639
Asymptomatic at first exam	4.4%	—
Intraretinal (bone-spicule) pigmentation	89.2%	HP:0007737
Attenuated retinal vessels	94.6%	HP:0007843
Macular changes	58.5%	HP:0001103 (Atypical/macular abnormality)
Optic disc waxy pallor	27.0%	HP:0000543 (Optic disc pallor)
Severe loss of fundus autofluorescence	55.3%	—
Hyper-autofluorescent ring	23.8%	—

Age of onset: Median first symptoms at 7 years (IQR 2.25–12); median baseline exam age 20 years. Onset is childhood, distinctly earlier than typical autosomal RP.

Severity/progression: Rapid and progressive. - BCVA: median 0.66 logMAR at baseline → 1.3 logMAR at last visit; progression rate of 46–49% acuity loss per decade; legal blindness reached by a median age of 27 years. - Central retinal thickness declining 12.6–13.9% per decade; photoreceptor+RPE complex declining 27–33.9% per decade. - Ellipsoid zone intact in only 34.3% at baseline (median age 14.5y) vs. severely disrupted/atrophic in 65.7% (median age 35y); EZ becomes "largely not measurable from 25 years of age." - Overall course: "rapid progression to outer retina atrophy and early macular involvement with substantial vision loss by age 30–40."

High myopia is a recognized associated feature, and fundus appearance can mimic choroideremia (per PreventionGenetics/differential diagnosis literature) without choroideremia-gene involvement — an important diagnostic pitfall.

Female carriers — from cohort of 27 carriers/21 pedigrees (PMC11139645, AJO 2023/2024):

85% asymptomatic with normal vision; 15% with RP-level complaints
Fundus: normal (30%), tapetal-like reflex/TLR (37%), scattered peripheral pigment (19%), overt RP changes (15%)
Visual acuity (WHO criteria): no/mild impairment 89%, moderate 3.7%, blind 7.4%
Full-field ERG abnormal in 82% (9/11 tested), often asymmetric
Radial fundus autofluorescence pattern in virtually all TLR carriers
Slowly progressive atrophic changes documented over 6.7–11.4 years in symptomatic carriers

Quality of life impact: No RP2-specific QOL study was found, but the broader XLRP burden literature (EXPLORE XLRP-2 study, PMC11794432, Eye 2025) is informative: among 169 XLRP patients (RPGR-predominant cohort), anxiety was reported by 74.2% and depression by 15.8%; severe disease correlated with difficulties in low-luminance function, employment, and mobility; mean diagnostic delay from symptom onset to genetic diagnosis was 16.4 years. These burden patterns are considered broadly applicable to RP2-XLRP given phenotypic overlap.

Suggested HPO terms: HP:0000546 (Retinal degeneration/atrophy), HP:0000662 (Nyctalopia), HP:0000639 (Nystagmus), HP:0007737 (Bone spicule pigmentation), HP:0007843 (Attenuation of retinal blood vessels), HP:0000543 (Optic disc pallor), HP:0000505 (Visual impairment), HP:0000545 (Myopia), HP:0000577 (Exotropia — if applicable), HP:0000512 (Abnormal electroretinogram).

4. Genetic/Molecular Information

Causal gene: RP2 (HGNC:10295), OMIM *300757, chromosome Xp11.3, NCBI Gene ID 6102. Encodes a 350-amino-acid, ubiquitously plasma-membrane/ciliary-localized protein.

Protein domain structure (UniProt O75695 / GeneCards): - N-terminal domain: homologous to tubulin-specific chaperone cofactor C (a β-helix domain involved in tubulin GTPase activation) - C-terminal domain: homology to nucleoside diphosphate kinases (NDK); "the physiological function of the NDK domain in RP2 remains to be determined" though it has also been reported to have 3'→5' exonuclease activity and nuclear translocation after DNA damage (ScienceDirect, S001448270500621X)

Variant classification/type (ClinVar, PMC9738434, PMC11139645): - Nonsense, frameshift, splice-site, missense, and whole/partial gene deletions - In the 47-male natural history cohort: 24 total variants (13 novel) — 5 nonsense, 6 frameshift, 1 splice-site, 1 missense (proportions approximate; most common: c.352C>T p.(Arg118Cys) and c.358C>T p.(Arg120)) - In the 21-pedigree carrier cohort: frameshift 28.6%, nonsense 28.6%, missense 23.8%, plus splice-site, whole-gene deletion, and smaller deletions - ClinVar: "39 ClinVar submitters have submitted clinical-significance assessments... after 2014, and all submitters classified the variants as pathogenic or likely pathogenic" — reflecting high consensus once a variant is curated, per ACMG/AMP framework - Up to 133 disease-associated variants* have been reported across the literature (PMC3124502)

Functional consequences: Frameshift/nonsense variants generally cause complete loss of function via truncation/nonsense-mediated decay; missense variants show variable pathogenic potential — some behave as near-null, others as partial hypomorphs (PMC3124502, "Functional Analysis of RP2 Protein Reveals Variable Pathogenic Potential of Disease-Associated Missense Variants"). Missense variants clustering in the ARL3-binding/N-terminal domain most consistently impair GAP activity; notably in the female carrier study, "no carriers with [ARL3-binding domain] variants were affected," while variants in the ferredoxin-like/β-helix domains were more often associated with an affected carrier phenotype — suggesting domain-specific severity even though no clear genotype-phenotype correlation was found in the male cohort.

Protein function/mechanism: RP2 acts as a GTPase-activating protein (GAP) for ARL3 (ADP-ribosylation factor-like 3), a small ciliary GTPase (Reactome R-HSA-5638007). RP2 stimulates GTP hydrolysis on ARL3-GTP, triggering release of UNC119(B)-bound lipidated cargo (e.g., transducin, NPHP3) at the ciliary base/membrane — a key step in selective ciliary protein trafficking.

Modifier genes: None validated; X-inactivation pattern (not a second gene) is the principal modifier of female carrier phenotype.

Epigenetic information: X-chromosome inactivation (Lyonization) is the central "epigenetic" determinant of phenotype expression in female carriers — this is not a disease-specific epigenetic mechanism but the generic mechanism underlying all X-linked carrier variability.

Chromosomal abnormalities: Contiguous gene deletions spanning RP2 and neighboring genes cause a distinct contiguous gene deletion syndrome, OMIM #300455 (X-linked RP with sinorespiratory infections ± deafness), illustrating that large deletions removing RP2 plus adjacent loci produce a syndromic phenotype beyond isolated retinopathy.

Suggested ontology terms: GO:0005096 (GTPase activator activity), GO:0060271 (cilium assembly), GO:0035861 (site of double-strand break — n/a), GO:0060170 (ciliary membrane), GO:0032391 (photoreceptor connecting cilium).

5. Environmental Information

No established environmental toxins, occupational exposures, or lifestyle factors are causally linked to RP2-related retinopathy — it is fully genetically determined. No infectious agents are implicated. (Not applicable beyond the general RP literature on vitamin A/E supplementation discussed under Treatment/Prevention.)

6. Mechanism / Pathophysiology

Causal chain: Pathogenic RP2 variant → loss/reduction of RP2 GAP activity toward ARL3 → failure of ARL3-GTP hydrolysis → impaired release of UNC119-bound lipidated cargo (transducin, and related proteins) at the photoreceptor connecting cilium → mistrafficking of phototransduction proteins into/through the outer segment → progressive photoreceptor dysfunction and death.

Molecular pathway specifics: - RP2-ARL3-UNC119 axis governs trafficking of lipidated proteins (e.g., farnesylated/prenylated cargo) across the connecting cilium (PMC5808637; Reactome R-HSA-5638007). - RP2/ARL3 also regulate trafficking of the ciliary tip kinesins KIF7 and KIF17, needed for intraflagellar transport (IFT)-related delivery to the cilium tip. - RP2 additionally supports Golgi cohesion and general vesicle trafficking/tubulin folding (via its cofactor-C-like domain), important for delivering opsins and other outer-segment cargo from the Golgi to the base of the connecting cilium.

Cellular processes: Impaired intracellular/intraciliary protein trafficking → progressive rod and cone photoreceptor degeneration via apoptosis; in RP2-knockout mouse and iPSC-organoid models, cone opsin (M-opsin) and rhodopsin mistrafficking, and diminished cone-specific GRK1 and PDE6 localization in outer segments, precede overt cell death.

Protein dysfunction: Predominantly loss of function (nonsense/frameshift/deletions) with some missense alleles causing partial or dominant-negative dysfunction of GAP activity (PMC3124502).

Tissue damage mechanism: Chronic photoreceptor-intrinsic ciliary trafficking failure leads to progressive apoptotic photoreceptor loss beginning with rods (nyctalopia) and extending to cones and RPE/outer retina (macular/central involvement), culminating in outer retinal atrophy.

Molecular profiling (model systems): - iPSC-derived retinal organoid transcriptomic/histologic data (Stem Cell Reports 2020, PMC7363745): CRISPR RP2-knockout and R120X patient-derived organoids show peak rod photoreceptor cell death around day 150 of culture and outer nuclear layer thinning by day 180; AAV-mediated RP2 gene augmentation rescued ONL thinning and restored rhodopsin expression. - Mouse knockout models show early cone dysfunction (mistrafficking of cone opsin, GRK1, PDE6) preceding degeneration, described as "early-onset cone dysfunction, followed by progressive cone degeneration, mimicking cone vision impairment in XLRP patients," though overall murine phenotype is milder than human disease.

Suggested GO/CL terms: GO:0007601 (visual perception), GO:0035845 (photoreceptor cell outer segment organization), GO:0006915 (apoptotic process), CL:0000210 (photoreceptor cell), CL:0000573 (retinal cone cell), CL:0000604 (retinal rod cell), CL:0000232 (retinal pigment epithelial cell — via GO:0032391 connecting cilium).

7. Anatomical Structures Affected

Organ level: Primary organ — the eye/retina (neurosensory retina, primarily photoreceptor layer; RPE secondarily). No consistent extra-ocular organ involvement in isolated RP2 disease, though contiguous-gene deletion cases (OMIM #300455) add sinorespiratory and hearing involvement (UBERON:0000949 endocrine — n/a; UBERON:0001004 respiratory system; UBERON:0001846 - middle ear structures for deafness).

Tissue/cell level: Rod photoreceptors (affected earliest — nyctalopia), cone photoreceptors (progressive involvement, central/macular vision loss), retinal pigment epithelium (atrophy with disease progression). Cell Ontology: CL:0000604 (rod), CL:0000573 (cone), CL:0002586 (retinal pigment epithelial cell).

Subcellular level: Connecting cilium / ciliary transition zone of photoreceptors (GO:0032391); Golgi apparatus (vesicle sorting, GO:0005794); outer segment membrane disc trafficking machinery.

Localization: Bilateral, generally symmetric in males; asymmetric/unilateral presentations reported in female carriers and rare male case reports (PMC10190057 — "asymmetric presentation with a novel RP2 gene mutation"). UBERON:0000966 (retina), UBERON:0001782 (macula lutea, for macular involvement).

8. Temporal Development

Onset: Pediatric/childhood — median age at first symptom 7 years in males; insidious onset of nyctalopia, sometimes with early nystagmus in infancy signaling more severe congenital-onset disease.

Progression: Rapid and relentlessly progressive (not episodic or relapsing-remitting). - Early stage (childhood–adolescence): nyctalopia, peripheral field constriction, intact ellipsoid zone in a minority - Intermediate stage (teens–20s): progressive EZ disruption, vessel attenuation, bone-spicule pigment - Advanced stage (30s–40s): outer retinal atrophy, macular involvement, legal blindness by median age 27 - Disease course pattern: chronic, lifelong, progressive (not self-limited); "46–49% BCVA loss per decade" quantifies the rate.

Patterns: No spontaneous remission described. In female carriers, disease can remain stable and mild for decades if X-inactivation favors the wild-type allele, or progress "slowly" (documented over 6.7–11.4 year follow-up) if unfavorably skewed. No defined "critical window" for intervention is established in the human literature, though preclinical gene-therapy rescue data (mouse, organoid) suggest earlier intervention (before extensive photoreceptor loss) yields better structural/functional rescue.

9. Inheritance and Population

Epidemiology: RP overall affects ~1/3,000–5,000; XLRP accounts for 5–15% of all RP and has a worldwide prevalence of roughly 1:30,000–1:40,000. Within XLRP, RPGR accounts for ~60–75% of cases and RP2 accounts for approximately 10–20% (estimates range 5–20% depending on cohort; PMC3124502, PMC5353642). No RP2-specific population prevalence figure was identified in the literature searched.

Inheritance pattern: X-linked — historically described as X-linked recessive, though the existence of a substantial fraction of symptomatic female carriers (documented above) means the disease is now often characterized as showing quasi-dominant or intermediate/semi-dominant inheritance with sex-limited penetrance modulated by X-inactivation, rather than "true" recessive inheritance.

Penetrance: Complete in hemizygous males; incomplete and variable in heterozygous females (only 15% symptomatic in the reviewed cohort), governed by random X-inactivation skewing.

Expressivity: Highly variable, especially in females (ranging from normal fundus to full RP); in males, expressivity is more uniform/severe, though the natural history study found no genotype-phenotype correlation across variant types.

Genetic anticipation: Not reported/not applicable (not a repeat-expansion disorder).

Germline mosaicism: Not specifically quantified in the reviewed literature for RP2, though it is a general consideration in X-linked disorder genetic counseling.

Founder effects/geographic distribution: No major founder mutations for RP2 were identified in the searched literature (contrast with RPGR ORF15 mutational hotspot, which accounts for ~2/3 of RPGR disease alleles). RP2 variants are described as diverse and largely private/family-specific across cohorts (Chinese, European/US cohorts referenced).

Consanguinity role: Not a significant factor given X-linked (not autosomal recessive) inheritance.

Carrier frequency: Not specifically reported; inferred to be very low given rarity of RP2 pathogenic alleles (private variants predominating over founder alleles).

Sex ratio: Disease manifests fully in males; females are carriers with variable, generally milder or absent phenotype — consistent with the essentially exclusive-male full phenotype pattern of X-linked RP.

Age distribution: Concentrated diagnosis in childhood-to-young-adult males (median baseline age in cohort 20 years); carrier females identified across a broad age range (16–76 years in the reviewed cohort) since many are ascertained through family cascade testing rather than symptoms.

10. Diagnostics

Clinical tests: - Fundus examination/fundus photography: bone-spicule pigmentation, vessel attenuation, waxy disc pallor - Fundus autofluorescence (FAF): hyperautofluorescent ring (parafoveal), radial pattern in carriers, progressive loss of AF signal - Optical coherence tomography (OCT/SD-OCT): ellipsoid zone (EZ) width/loss, central retinal thickness, photoreceptor+RPE complex thickness — all quantified with defined decline rates in the natural history study - Full-field electroretinography (ff-ERG): rod-cone dysfunction pattern, often severely reduced/non-recordable in advanced male disease; abnormal in 82% of tested carriers - Pattern ERG (PERG): used to detect macular dysfunction in carriers - Visual field testing: documents peripheral constriction - Visual acuity (BCVA, logMAR): primary functional endpoint tracked longitudinally

Genetic testing: - Single-gene RP2 sequencing or targeted XLRP gene panels (RP2 + RPGR ORF15 + OFD1, ± broader IRD panels) are the standard approach given clinical overlap - Whole exome/genome sequencing used when panel testing is non-diagnostic or phenotype is atypical - Chromosomal microarray: relevant when contiguous gene deletion (OMIM #300455) is suspected (e.g., syndromic features — deafness, recurrent sinorespiratory infection) - Sanger confirmation and segregation analysis in relatives remains standard for variant classification - No mitochondrial, repeat-expansion, or karyotype-specific testing is routinely indicated for isolated RP2 disease

Clinical criteria/differential diagnosis: Diagnosis relies on typical RP fundus/ERG findings plus X-linked pedigree pattern and confirmed hemizygous RP2 variant. Key differentials: RPGR-associated XLRP (most common XLRP gene; ORF15 mutational hotspot), choroideremia (RP2 disease can closely mimic choroideremia fundus appearance without CHM involvement — an important diagnostic pitfall noted in PreventionGenetics literature), autosomal RP forms, and other syndromic ciliopathies given RP2's ciliary function.

Screening: No population newborn screening; family cascade genetic testing/counseling is the main "screening" modality for at-risk relatives (particularly potential female carriers, given the significant proportion who are symptomatic).

11. Outcome/Prognosis

Visual prognosis (not life-threatening — an isolated ocular disease): - Legal blindness reached at a median age of 27 years in the male cohort - BCVA loss of ~46–49% per decade; substantial vision loss by age 30–40 - Structural retinal decline (EZ, CRT, PR+RPE thickness) parallels functional loss, with EZ becoming unmeasurable from age 25 onward in many patients — indicating this as a useful structural endpoint for future trials - Carrier females: prognosis is bimodal — majority retain good vision lifelong; a minority (~15% symptomatic, up to 7.4% legally blind in the reviewed cohort) progress to significant visual impairment

Morbidity/QOL: Drawing on the broader XLRP burden literature (EXPLORE XLRP-2), patients with severe disease show substantially higher rates of anxiety (74.2%), depression (15.8%), and impaired mobility/employment/daily functioning; diagnostic delay averages 16.4 years from symptom onset, a modifiable systemic factor affecting timely counseling and trial eligibility.

Complications: Cystoid macular edema and cataract can complicate advanced RP generally (not RP2-specific data identified); high myopia is a recognized associated ocular feature.

Prognostic factors: Earlier nystagmus at presentation may signal more severe/congenital-onset disease; no genotype-phenotype correlation has been established for variant type/location predicting severity in males. In females, X-inactivation skewing is the dominant prognostic determinant.

12. Treatment

Pharmacotherapy: No approved disease-modifying drug specific to RP2. General RP literature suggests vitamin A palmitate supplementation may modestly slow progression in some RP forms (evidence is weak/"insubstantial"), while high-dose vitamin E should be avoided (documented adverse effect on RP progression in the DHOM/Berson-type trials). No RP2-specific pharmacogenomic data exists.

Gene therapy (most promising avenue, preclinical/early translational stage): - AAV8/AAV9-mediated RP2 gene augmentation (full-length human RP2 coding sequence) has shown efficacy in RP2-knockout mouse models, achieving "long-term rescue of cone photoreceptor degeneration" (PMC4626763) and in iPSC-derived retinal organoids (isogenic RP2-knockout and R120X patient-derived), where AAV-RP2 "rescued the degeneration phenotype... preventing outer nuclear layer thinning and restoring rhodopsin expression" (Stem Cell Reports 2020, PMC7363745). - As of the literature reviewed, no RP2-specific gene therapy has yet reached registered human clinical trials (unlike RPGR, for which AGTC-501/laruparetigene zosaparvovec and 4D-125 are in Phase 1/2/3 trials, NCT04850118 and NCT04517149). RP2 vectors have been described as advancing toward clinical stage (NIH Tech Transfer listing) but a registered NCT trial specific to RP2 was not identified in this search.

Surgical/interventional: Argus II retinal prosthesis (FDA-approved for severe-to-profound RP of any genetic cause, age >25) is applicable to end-stage RP2 disease as a vision-restoration option, delivering electrical stimulation to surviving retinal cells via an epiretinal electrode array.

Supportive/rehabilitative: Low-vision aids, portable/adaptive lighting, orientation and mobility training, and genetic counseling are mainstays of current management.

Experimental: Retinal organoid and AAV vector platforms remain the primary experimental therapeutic pipeline; no RNA-based (ASO/siRNA) or small-molecule targeted therapy for RP2 was identified.

Suggested MAXO terms: MAXO term for "gene replacement therapy" (AAV-mediated gene augmentation), "retinal prosthesis implantation" (Argus II), "low vision rehabilitation," "genetic counseling," "dietary supplementation" (vitamin A).

13. Prevention

Primary prevention: Not applicable in the traditional sense (monogenic disease); genetic counseling and carrier testing for at-risk female relatives is the principal preventive strategy, given that carrier detection informs reproductive decision-making.

Secondary prevention/screening: Cascade genetic testing in families with a known RP2 variant; given that ~15% of female carriers are symptomatic, comprehensive ophthalmologic and genetic evaluation of at-risk females (not just male relatives) is recommended.

Reproductive options: Prenatal testing and preimplantation genetic diagnosis (PGD) are available options for known carrier families, following standard X-linked disorder genetic counseling frameworks (ACMG/NSGC), though no RP2-specific PGD outcome data was identified.

Tertiary prevention: Regular monitoring (OCT, FAF, ERG) to time low-vision intervention and clinical trial eligibility; avoidance of vitamin E supplementation; UV/blue-light protection is commonly recommended in general RP care (photoreceptor stress reduction), though direct RP2 evidence is lacking.

14. Other Species / Natural Disease

Taxonomy: Mus musculus (NCBI Taxon 10090) — Rp2-knockout mouse models exist; Danio rerio (NCBI Taxon 7955) — TALEN-generated rp2 knockout zebrafish.

Canine models — clarification: Initial search results returned OMIA:001518-9615 ("X-linked progressive retinal atrophy, type 2," XLPRA2) which is actually caused by RPGR ORF15 mutations, not RP2 — this is an important distinction to avoid conflating the two XLRP genes. No well-characterized naturally-occurring canine ortholog model specific to RP2 was identified in this search; canine XLPRA1/XLPRA2 remain the standard dog models for XLRP generally (via RPGR) and are useful comparators given similarities in ciliary photoreceptor biology.

Gene orthologs: Mouse Rp2 (MGI ortholog of human RP2), zebrafish rp2.

Comparative biology: Rp2-knockout mice show a milder phenotype than human disease — early cone-specific opsin/GRK1/PDE6 mistrafficking (as early as 2 months in one model, with ONL thinning by 5 months; another model showed abnormalities only by 14 months) followed by slow degeneration, useful for mechanistic study and therapy testing but not fully recapitulating the rapid, severe human course. Zebrafish rp2 knockouts show mild visual impairment (30% reduction in scotopic ERG b-wave) at 7 days post-fertilization. iPSC-derived retinal organoids (human, isogenic knockout and patient-derived) more directly recapitulate rod-predominant degeneration with defined kinetics (peak cell death ~day 150, ONL thinning by day 180) and have been used successfully for AAV rescue proof-of-concept.

Transmission/zoonotic potential: Not applicable (non-infectious genetic disease).

15. Model Organisms Summary